Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.8.3691

Association between RASSF1A Ala133Ser Polymorphism and Cancer Susceptibility: A Meta-Analysis Involving 8,892 Subjects  

Bayram, Suleyman (Department of Nursing, School of Health, Adıyaman University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.8, 2014 , pp. 3691-3698 More about this Journal
Abstract
Background: Published studies on the association between the Ras Association Domain Family 1 isoform A (RASSF1A) Ala133Ser polymorphism and cancer susceptibility have yielded conflicting results. Thus, a meta-analysis was here performed to assess the possible association. Materials and Methods: All eligible case-control studies published up to November 2013 on the association between RASSF1A Ala133Ser polymorphism and cancer susceptibility were identified by searching PubMed, Web of Science, Science Direct and hand search. Bothfixed-effect and random-effect models were used to calculate pooled odds ratios (ORs) with 95% confidence intervals (CIs) by using the Comprehensive Meta-Analysis software version 2.2. Results: A total of 10 studies including 4,572 cancer cases and 4,320 controls were included in the meta-analysis. Overall, significantly increased cancer risk was associated with the variant Ser133 when all studies were pooled (Ser vs Ala: OR=1.51, 95% CI=1.08-2.12, $P_{heterogeneity}{\leq}0.001$; Ser/Ser+Ala/Ser vs Ala/Ala: OR=1.55, 95% CI=1.08-2.22, $P_{heterogeneity}{\leq}0.001$). Moreover, in subgroup analyses by cancer types, a significant association between RASSF1A Ala133Ser polymorphism and lung cancer risk was found (Ser vs Ala: OR=2.27, 95% CI=1.29-4.02, $P_{heterogeneity}$=0.61; Ser/Ser+Ala/Ser vs Ala/Ala: OR=2.42, 95% CI=1.33-4.42, $P_{heterogeneity}=0.75$). In addition, in subgroup analyses by ethnicity, it was found that the RASSF1A Ala133Ser polymorphism was associated with overall cancer risk in Asians (Ser vs Ala: OR=1.37, 95% CI=1.06-1.77, $P_{heterogeneity}=0.06$) and Caucasians (Ser/Ser+Ala/Ser vs Ala/Ala: OR=2.21, 95% CI=1.01-4.82, $P_{heterogeneity}{\leq}0.001$). Conclusions: This meta-analysis suggests, for the first time, that RASSF1A Ala133Ser polymorphism may contribute to cancer susceptibility, especially for lung cancer. Besides, additional well-designed studies with larger sample size focusing on different ethnicities and cancer types are needed to confirm these findings.
Keywords
RASSF1A; RASSF1A Ala133Ser polymorphism; cancer susceptibility; meta-analysis;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
2 Qin Q, Zhang C, Zhu H, et al (2014). Association between survivin-31G>C polymorphism and cancer risk: metaanalysis of 29 studies. J Cancer Res Clin Oncol, 140, 179-88.   DOI   ScienceOn
3 Richter AM, Pfeifer GP, Dammann RH (2009). The RASSF proteins in cancer; from epigenetic silencing to functional characterization. Biochim Biophys Acta, 1796, 114-28.
4 Schagdarsurengin U, Seidel C, Ulbrich EJ, et al (2005). A polymorphism at codon 133 of the tumor suppressor RASSF1A is associated with tumorous alteration of the breast. Int J Oncol, 27, 185-91.
5 Shivakumar L, Minna J, Sakamaki T, Pestell R, White MA (2002). The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation. Mol Cell Biol, 22, 4309-18.   DOI   ScienceOn
6 van der Weyden L, Adams DJ (2007). The Ras-association domain family (RASSF) members and their role in human tumourigenesis. Biochim Biophys Acta, 1776, 58-85.
7 Donninger H, Barnoud T, Nelson N, et al (2011). RASSF1A and the rs2073498 cancer associated SNP. Front Oncol, 1, 54.
8 Bergqvist J, Latif A, Roberts SA, et al (2010). RASSF1A polymorphism in familial breast cancer. Fam Cancer, 9, 263-5.   DOI
9 Borenstein M, Hedges L, Higgins J, Rothstein H (2007). Comprehensive Meta-analysis version 2. Biostat, Inc. Englewood, NJ.
10 DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88.   DOI   ScienceOn
11 Xiao G, Zhang T, Yao J, et al (2009). The association between RASSF1 gene polymorphisms and lung cancer susceptibility among people in Hubei Province of China. J Huazhong Univ Sci Technolog Med Sci, 29, 646-9.   DOI   ScienceOn
12 Zhou SL, Cui J, Fan ZM, et al (2013). Polymorphism of A133S and promoter hypermethylation in Ras association domain family 1A gene (RASSF1A) is associated with risk of esophageal and gastric cardia cancers in Chinese population from high incidence area in northern China. BMC Cancer, 13, 259.   DOI   ScienceOn
13 Meyer A, Coinac I, Bogdanova N, et al (2013). Apoptosis gene polymorphisms and risk of prostate cancer: a hospital-based study of German patients treated with brachytherapy. Urol Oncol, 31, 74-81.   DOI   ScienceOn
14 Kawai Y, Sakano S, Okayama N, et al (2012). Association of genotype and haplotype with the progression of clear cell renal cell carcinoma in Japanese patients. BJU Int, 110, 1070-5.   DOI   ScienceOn
15 Liu WJ, Tan XH, Guo BP, et al (2013). Associations between RASSF1A promoter methylation and NSCLC: a metaanalysis of published data.. Asian Pac J Cancer Prev, 14, 3719-24.   과학기술학회마을   DOI   ScienceOn
16 Donninger H, Vos MD, Clark GJ (2007). The RASSF1A tumor suppressor. J Cell Sci, 120, 3163-72.   DOI   ScienceOn
17 Egger M, Davey Smith G, Schneider M, Minder C (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34.   DOI   ScienceOn
18 El-Kalla M, Onyskiw C, Baksh S (2010). Functional importance of RASSF1A microtubule localization and polymorphisms. Oncogene, 29, 5729-40.   DOI   ScienceOn
19 Gao B, Xie XJ, Huang C, et al (2008). RASSF1A polymorphism A133S is associated with early onset breast cancer in BRCA1/2 mutation carriers. Cancer Res, 68, 22-5.   DOI   ScienceOn
20 Gordon M, Baksh S (2011). RASSF1A: not a prototypical Ras effector. Small GTPases, 2, 148-57.   DOI
21 Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003). Measuring inconsistency in meta-analyses. BMJ, 327, 557-60.   DOI   ScienceOn
22 Higgins JP, Thompson SG (2002). Quantifying heterogeneity in a meta-analysis. Stat Med, 21, 1539-58.   DOI   ScienceOn
23 Kanzaki H, Hanafusa H, Yamamoto H, et al (2006). Single nucleotide polymorphism at codon 133 of the RASSF1 gene is preferentially associated with human lung adenocarcinoma risk. Cancer Let, 238, 128-34.   DOI   ScienceOn
24 Akkız H, Bayram S, Bekar A, Akgollu E, Uskudar O (2011). Genetic variation in the MicroRNA-499 gene and hepatocellular carcinoma risk in a Turkish population: lack of any association in a case-control study. Asian Pac J Cancer Prev, 12, 3107-12.
25 Bayram S, Akkız H, Bekar A, Akgollu E, Yıldırım S (2011). No association of exonuclease 1 T439M polymorphism and risk of hepatocellular carcinoma development in Turkish population: a case-control study. Asian Pac J Cancer Prev, 12, 2455-60.
26 Vo LT, Thuan TB, Thu DM, et al (2013). Methylation profile of BRCA1, RASSF1A and ER in Vietnamese women with ovarian cancer.. Asian Pac J Cancer Prev, 14, 7713-8..   과학기술학회마을   DOI   ScienceOn
27 Bayram S (2012). RASSF1A Ala133Ser polymorphism is associated with increased susceptibility to hepatocellular carcinoma in a Turkish population. Gene, 498, 264-9.   DOI   ScienceOn
28 Begg CB, Mazumdar M (1994). Operating characteristics of a rank correlation test for publication bias. Biometrics, 50, 1088-101.   DOI   ScienceOn